



Amgen Limited  
240 Cambridge Science Park  
Milton Road  
Cambridge  
CB4 0WD  
Tel: +44 (0)1223 420305  
UK Freephone: 0800 243104  
Fax: +44 (0)1223 423049

23<sup>rd</sup> January 2008

Dear Healthcare Professional

**Paediatric Chronic Renal Failure Patients on Maintenance Aranesp<sup>®</sup>**

I would like to inform you of an error within section 4.2, Posology and Method of Administration, of the Summary of Product Characteristics for both Aranesp<sup>®</sup> (darbepoetin alfa) pre-filled syringe and Aranesp<sup>®</sup> (darbepoetin alfa) SureClick<sup>™</sup>.

The administration details for paediatric patients with chronic renal failure in the maintenance phase should read as follows;

"For paediatric patients 1-18 years of age, clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Aranesp, and those receiving r-HuEPO once weekly may be converted to once every other week Aranesp. The initial weekly or once every other week paediatric dose of Aranesp ( $\mu\text{g}/\text{week}$ ) can be determined by dividing the total weekly dose of r-HuEPO (IU/week) by 240. Because of individual variability, titration to optimal therapeutic doses is expected for individual patients. When substituting Aranesp for r-HuEPO the haemoglobin should be monitored every one or two weeks and the same route of administration should be used."

Previously the highlighted text read as  $\mu\text{g}/\text{kg}$  which is incorrect.

Please refer to <http://emc.medicines.org.uk> or <http://www.medicines.ie> for the full correct prescribing information.

Alternatively please do not hesitate to contact me directly if you have any questions regarding this information.

Yours sincerely

Dr Charles Brigden  
Medical Director  
Amgen UK & Ireland  
01223 436302